News
Uncertainty can be a great thing for value investors, as that’s what creates bargain opportunities for those willing to take ...
3h
Zacks Investment Research on MSNInvestors Heavily Search Bristol Myers Squibb Company (BMY): Here is What You Need to KnowBristol Myers Squibb (BMY) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.
Onco360®, the nation’s leading independent specialty pharmacy, has added Augtyro™ (repotrectinib) manufactured by Bristol ...
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
After several PD-1xVEGF competitors forged alliances with Big Pharma players, Summit Therapeutics, the frontrunner in this hot cancer drug field, is reportedly seeking its own deal. | After several PD ...
The MachineCon GCC Summit 2025 celebrated industry leaders with the GCC Excellence Awards, recognising exceptional ...
Coverage from “Tech Innovations in Oncology,” presented June 19, 2025, by Tennessee Oncology in Nashville, Tennessee. First ...
TIGIT-targeting therapies have largely disappointed in recent months, with failed studies, terminated partnerships and ...
3h
Zacks Investment Research on MSNHow to Maximize Your Retirement Portfolio with These Top-Ranked Dividend StocksHere's an eye-opening statistic: older Americans are more afraid of running out of money than of death itself. And older Americans have legitimate reasons for this worry, even if they have dutifully ...
Bristol-Myers Squibb is testing MORAb-202 in a Phase 2 trial to challenge traditional chemotherapy for platinum-resistant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results